254 related articles for article (PubMed ID: 26141568)
1. Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.
Pery E; Sheehy A; Miranda Nebane N; Misra V; Mankowski MK; Rasmussen L; Lucile White E; Ptak RG; Gabuzda D
Virology; 2015 Oct; 484():276-287. PubMed ID: 26141568
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
5. Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein.
Pan T; He X; Chen B; Chen H; Geng G; Luo H; Zhang H; Bai C
Eur J Med Chem; 2015 May; 95():500-13. PubMed ID: 25847768
[TBL] [Abstract][Full Text] [Related]
6. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
7. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
Chaipan C; Smith JL; Hu WS; Pathak VK
J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
10. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibition of HIV-1 Vif.
Nathans R; Cao H; Sharova N; Ali A; Sharkey M; Stranska R; Stevenson M; Rana TM
Nat Biotechnol; 2008 Oct; 26(10):1187-92. PubMed ID: 18806783
[TBL] [Abstract][Full Text] [Related]
12. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
[TBL] [Abstract][Full Text] [Related]
13. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
Martin KL; Johnson M; D'Aquila RT
J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
[TBL] [Abstract][Full Text] [Related]
14. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
15. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
17. Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1.
Bao Q; Zhou J
Eur J Med Chem; 2023 Mar; 250():115188. PubMed ID: 36773550
[TBL] [Abstract][Full Text] [Related]
18. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
19. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
20. The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway.
Zhou D; Wang Y; Tokunaga K; Huang F; Sun B; Yang R
Virus Res; 2015 Jan; 195():25-34. PubMed ID: 25200749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]